Meihua Group to acquire Dalian Hanxin Bio

Meihua Group announced that the company and Tibet Yiyuan Industrial Co., Ltdreached a framework agreement to invest in the acquisition of Yiyuan Industrial holding stake in Dalian Hanxin Biopharmaceutical Co., Ltd("Hanxin Bio") 100%, the specific purchase price reference evaluation results pricing59J
It is reported that in the current widespread attention to the suspected hepatitis B vaccine death incident, Dalian Hanxin was also involvedAccording to media reports, on December 21, 2013, a baby boy in Yongjia, Zhejiang Province, died after being vaccinated against hepatitis B on the morning of the 20th, and the hepatitis B vaccine used was produced by Dalian Hanxin, the incident is still awaiting the results of an autopsy59J
In addition, net ease financial has previously reported that, because has not yet passed the new version of GMP certification, Dalian Hanxin's hepatitis B vaccine production line is currently in a state of shutdownIt is reported that the new version of GMP is the "Good Manufacture Practice" abbreviation, is the rationality of the production process of enterprises, the applicability of production equipment and the accuracy of production operations, the specification of mandatory requirements59J
According to Decree No79 of 2011 signed by the Minister of Health of the People's Republic of China, the Code of Quality Management of Pharmaceutical Production (revised in 2010) (hereinafter referred to as the new version of GMP) was approved by the Ministry of Health's Ministerial Council on October 19, 2010 and came into effect on March 1, 2011Compared with the 98 version of China's new GMP, there have been considerable progress in management and technical requirements, especially in the production of sterile preparations and API59J
　　The Ministry of Health website shows that the new version of GMP certification has two time nodes: pharmaceutical manufacturers blood products, vaccines, injections and other sterile drugs production, should be reached by December 31, 2013 new version of the drug GMP requirements; Enterprises (workshops) that do not meet the GMP requirements for the new version of the drug may not continue to produce drugs after the above-mentioned period 59J
　　And Dalian Hanxin Administrative Office staff to NetEase Financial confirmed that the company has not yet passed the new version of GMP certification, and said that the company has submitted to the relevant departments of the state of the new version of the GMP certification application, but has not yet obtained "We expect to be certified as a new GMP in the second half of next year." He also pointed out to NetEase Finance that before the new version of GMP certification, Dalian Hanxin's hepatitis B vaccine production will indeed be greatly affected "Until the new GMP certification is obtained, the company's hepatitis B vaccine production will temporarily stall However, this does not affect the sale and use of hepatitis B vaccine produced before January 1, 2014, and the company currently has a certain inventory, I believe it can support for some time." 59J
　　According to china merchants securities statistics show that in the first 10 months of 2013, the hepatitis B vaccine market issued a total of 91.07 million bottles, an increase of 101.9% year-on-year Among them, Dalian Hanxin 26.47 million bottles, accounting for 29%, and Temple of Heaven 23.53 million bottles, accounting for 25.8% 59J
　　The announcement shows that Hanxin Bio was founded in September 1993, is an earlier start-up in china specializing in vaccine production, research and development, sales of high-tech enterprises At present, the registered capital of 160 million yuan, the business scope is mainly for vaccines, pills, small-volume injections, freeze-dried powder needle research, production and sales Hansin Bio's current listed varieties include the Recombinant Hepatitis B vaccine (Hanson yeast) and the human rabies vaccine (ground rat kidney cells), and the new investment in the new influenza lysis vaccine product is also on the market "Hepatitis B vaccine is a major national 863 science and technology projects undertaken by Hanxin Bio, with a production capacity of up to 30 million people per year, enjoying a very high visibility and influence in the market, and has been exported to countries such as Kyrgyzstan and Pakistan in Asia Another product ground mouse kidney cell rabies vaccine is the national "torch plan" project, is the largest production base of the product 59J
　　As of December 31, 2012, Hanxin Bio's total assets totaled 295 million yuan, net assets of 167 million yuan, and Dalian Hanxin's net profit for the 2012 year was 31.21 million yuan, the announcement said In response to the acquisition, Meihua Group said that after the acquisition, the company plans to use this as a platform for the integration of products and business, and on the basis of the existing introduction of the industry's top technical team to build the listed company's vaccine business segment "This acquisition will be an important first step for listed companies to enter the biopharmaceutical sector in a substantial way, and the acquisition is in line with the future development plans of listed companies and the interests of listed companies." 59J
　　Meihua Group, formerly known as Hebei Meihua MSG Group Co., Ltd., was established in April 2002 to produce and operate MSG-based industry, is the largest amino acid production enterprises in China, with an annual output of 500,000 tons of MSG At present, the main business covers amino acids and condiments two major areas, with food additives, pharmaceutical intermediates, feed additives, condiments and other four plates 59J Meihua Group announced that the company and Tibet Yiyuan Industrial Co., Ltd reached a framework agreement to invest in the acquisition of Yiyuan Industrial holding of Dalian Hanxin Biopharmaceutical Co., Ltd ("Hanxin Bio") 100% of the shares, the specific purchase price reference evaluation results price pricing 59J
　　It is reported that in the current widespread attention to the suspected hepatitis B vaccine death incident, Dalian Hanxin was also involved According to media reports, on December 21, 2013, a baby boy in Yongjia, Zhejiang Province, died after being vaccinated against hepatitis B on the morning of the 20th, and the hepatitis B vaccine used was produced by Dalian Hanxin, the incident is still awaiting the results of an autopsy 59J
　　In addition, net ease financial has previously reported that, because has not yet passed the new version of GMP certification, Dalian Hanxin's hepatitis B vaccine production line is currently in a state of shutdown It is reported that the new version of GMP is the "Good Manufacture Practice" abbreviation, is the rationality of the production process of enterprises, the applicability of production equipment and the accuracy of production operations, the specification of mandatory requirements 59J
　　According to Decree No 79 of 2011 signed by the Minister of Health of the People's Republic of China, the Code of Quality Management of Pharmaceutical Production (revised in 2010) (hereinafter referred to as the new version of GMP) was approved by the Ministry of Health's Ministerial Council on October 19, 2010 and came into effect on March 1, 2011 Compared with the 98 version of China's new GMP, there have been considerable progress in management and technical requirements, especially in the production of sterile preparations and API 59J
　　The Ministry of Health website shows that the new version of GMP certification has two time nodes: pharmaceutical manufacturers blood products, vaccines, injections and other sterile drugs production, should be reached by December 31, 2013 new version of the drug GMP requirements; Enterprises (workshops) that do not meet the GMP requirements for the new version of the drug may not continue to produce drugs after the above-mentioned period 59J
　　And Dalian Hanxin Administrative Office staff to NetEase Financial confirmed that the company has not yet passed the new version of GMP certification, and said that the company has submitted to the relevant departments of the state of the new version of the GMP certification application, but has not yet obtained "We expect to be certified as a new GMP in the second half of next year." He also pointed out to NetEase Finance that before the new version of GMP certification, Dalian Hanxin's hepatitis B vaccine production will indeed be greatly affected "Until the new GMP certification is obtained, the company's hepatitis B vaccine production will temporarily stall However, this does not affect the sale and use of hepatitis B vaccine produced before January 1, 2014, and the company currently has a certain inventory, I believe it can support for some time." 59J
　　According to china merchants securities statistics show that in the first 10 months of 2013, the hepatitis B vaccine market issued a total of 91.07 million bottles, an increase of 101.9% year-on-year Among them, Dalian Hanxin 26.47 million bottles, accounting for 29%, and Temple of Heaven 23.53 million bottles, accounting for 25.8% 59J
　　The announcement shows that Hanxin Bio was founded in September 1993, is an earlier start-up in china specializing in vaccine production, research and development, sales of high-tech enterprises At present, the registered capital of 160 million yuan, the business scope is mainly for vaccines, pills, small-volume injections, freeze-dried powder needle research, production and sales Hansin Bio's current listed varieties include the Recombinant Hepatitis B vaccine (Hanson yeast) and the human rabies vaccine (ground rat kidney cells), and the new investment in the new influenza lysis vaccine product is also on the market "Hepatitis B vaccine is a major national 863 science and technology projects undertaken by Hanxin Bio, with a production capacity of up to 30 million people per year, enjoying a very high visibility and influence in the market, and has been exported to countries such as Kyrgyzstan and Pakistan in Asia Another product ground mouse kidney cell rabies vaccine is the national "torch plan" project, is the largest production base of the product 59J
　　As of December 31, 2012, Hanxin Bio's total assets totaled 295 million yuan, net assets of 167 million yuan, and Dalian Hanxin's net profit for the 2012 year was 31.21 million yuan, the announcement said In response to the acquisition, Meihua Group said that after the acquisition, the company plans to use this as a platform for the integration of products and business, and on the basis of the existing introduction of the industry's top technical team to build the listed company's vaccine business segment "This acquisition will be an important first step for listed companies to enter the biopharmaceutical sector in a substantial way, and the acquisition is in line with the future development plans of listed companies and the interests of listed companies." 59J
　　Meihua Group, formerly known as Hebei Meihua MSG Group Co., Ltd., was established in April 2002 to produce and operate MSG-based industry, is the largest amino acid production enterprises in China, with an annual output of 500,000 tons of MSG At present, the main business covers amino acids and condiments two major areas, with food additives, pharmaceutical intermediates, feed additives, condiments and other four plates 59J
Share it on feed